Skip to main content

Our mission

We create inspired medicines that matter to cancer patients based on our expertise and ADC technologies

ADC Drug Development

We use the active ingredient Amanitin from the death cap mushroom for cancer therapies by researching, producing and clinically developing so-called Antibody Amanitin Conjugates.

ATACs belong to the class of Antibody Drug Conjugates (ADCs), which combine the high affinity and specificity of antibodies with the efficacy of small toxic molecules to fight cancer.


PR: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
05 April 2024
PR: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
27 March 2024
PR: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
25 March 2024
PR: Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
19 March 2024

Meet us

Deutsche Biotechnologietage
16. - 17. April
Kempen Life Science Conference
16. - 17. April
R&D-Webinar Heidelberg Pharma
23. April
PEGS Boston 2024
13. - 17. Mai

Partner Information

Telix: TLX250-CDx (Zircaix®) Recognised in EAU Guidelines as an Emerging Technology for the Management of RCC (Kidney Cancer)
12 April 2024
Read more
Telix: First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
25 March 2024
Read more
Telix: Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
19 December 2023
Read more